Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

NCT06698250 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Zanzalintinib
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Anwaar Saeed

Collaborators

[object Object]